Shorla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHORLA
SHORLA has four approved drugs.
There are four US patents protecting SHORLA drugs.
There are thirty-four patent family members on SHORLA drugs in twenty-three countries and ten supplementary protection certificates in seven countries.
Summary for Shorla
| International Patents: | 34 |
| US Patents: | 4 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Shorla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shorla | JYLAMVO | methotrexate | SOLUTION;ORAL | 212479-001 | Nov 29, 2022 | RX | Yes | Yes | 11,771,701 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shorla | NELARABINE | nelarabine | INJECTABLE;INTRAVENOUS | 214809-001 | Mar 3, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shorla | TEPYLUTE | thiotepa | SOLUTION;INTRAVENOUS | 216984-001 | Jun 25, 2024 | RX | Yes | Yes | 11,975,013 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shorla | JYLAMVO | methotrexate | SOLUTION;ORAL | 212479-001 | Nov 29, 2022 | RX | Yes | Yes | 11,129,833 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shorla | TEPYLUTE | thiotepa | SOLUTION;INTRAVENOUS | 216984-002 | Feb 26, 2025 | RX | Yes | Yes | 11,975,013 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shorla Oncology | IMKELDI | imatinib mesylate | SOLUTION;ORAL | 219097-001 | Nov 22, 2024 | RX | Yes | Yes | 11,957,681 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shorla Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3244102 | ⤷ Start Trial |
| United Kingdom | 201519049 | ⤷ Start Trial |
| Poland | 3212237 | ⤷ Start Trial |
| Portugal | 3212237 | ⤷ Start Trial |
| China | 119053320 | ⤷ Start Trial |
| San Marino | T202200104 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shorla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0564409 | 2002/005 | Ireland | ⤷ Start Trial | PRODUCT NAME: IMATINIB OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; NAT REGISTRATION NO/DATE: EU/1/01/198/001-006 20011107; FIRST REGISTRATION NO/DATE: CH 55807 55807 01 55807 02 20010621; PAEDIATRIC INVESTIGATION PLAN: P/0028/2012 |
| 0564409 | C00564409/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IMATINIB; REGISTRATION NO/DATE: IKS 55807 20010621 |
| 0294114 | 2007C/063 | Belgium | ⤷ Start Trial | PRODUCT NAME: NELARABINE; REGISTRATION NO/DATE: EU/1/07/403/001 20070823 |
| 0564409 | C300086 | Netherlands | ⤷ Start Trial | PRODUCT NAME: IMATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESILAAT; NATL. REGISTRATION NO/DATE: EU/1/01/198/001 - 006 20011107; FIRST REGISTRATION: CH IKS 55807 20010621 |
| 0294114 | C300302 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NELARABINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR BAAR ZOUT, ETHER OF ESTER; REGISTRATION NO/DATE: EU/1/07/403/001 20070822 |
| 0294114 | 07C0058 | France | ⤷ Start Trial | PRODUCT NAME: NELARABINE, OU L?UN DE SES DERIVES PHYSIOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/403/001 DU 20070822; REGISTRATION NO/DATE AT EEC: EU/1/07/403/001 DU 20070822 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
